Autoimmune hepatitis
MONDO:0016264Hepatitis caused by autoantibodies. Drugs, infections, and toxins may trigger the production of the autoantibodies against the liver parenchyma.
Also known as: autoimmune liver disease, autoimmune hepatitis, autoimmune chronic active hepatitis, autoimmune hepatitis with centrilobular necrosis, chronic autoimmune hepatitis, AIH, autoimmune chronic hepatitis
59 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
New drug aims to tame autoimmune hepatitis and cut steroid use
Disease control Not yet recruitingThis study tests a drug called inebilizumab in 180 adults with autoimmune hepatitis, a condition where the immune system attacks the liver. The goal is to see if the drug can reduce liver inflammation and allow patients to take lower doses of steroids. Participants will receive e…
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New drug combo aims to tame liver side effects of cancer immunotherapy
Disease control Not yet recruitingThis study tests whether combining mycophenolate mofetil (MMF) with prednisone can better treat liver inflammation caused by checkpoint inhibitor cancer drugs. The trial includes adults with moderate to severe immune-related hepatitis who need to pause their cancer therapy. The m…
Phase: PHASE2 • Sponsor: Fox Chase Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Experimental drug aims to tame stubborn autoimmune diseases
Disease control Not yet recruitingThis early study tests an experimental drug called STR-P005 in people with autoimmune diseases that have come back or not improved with standard treatments. The drug is given through an IV in multiple doses. The main goal is to check safety and see how the body handles the drug. …
Phase: NA • Sponsor: Starna Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a common liver drug replace steroids for immunotherapy side effects?
Disease control Not yet recruitingThis phase 2 trial tests whether ursodeoxycholic acid (UDCA), a drug already used for other liver conditions, can treat cholestatic hepatitis—a liver inflammation caused by immunotherapy—better than standard steroids. About 94 adults with cancer (excluding liver cancer) who devel…
Phase: PHASE2 • Sponsor: University Hospital, Montpellier • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for immunotherapy side effects: blood filtering may replace steroids
Disease control Not yet recruitingThis study tests a treatment called extracorporeal photopheresis (ECP) for people with advanced melanoma who develop severe colitis or hepatitis from immunotherapy. ECP filters a patient's blood, treats it with a light-activated drug, and returns it to the body. The trial compare…
Phase: PHASE2 • Sponsor: Therakos LLC • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New drug STR-P005 aims to tame stubborn autoimmune diseases
Disease control Not yet recruitingThis early study tests a new drug called STR-P005 in 18 people with autoimmune diseases that have not responded to standard treatments. The main goal is to check safety and find the best dose. Participants receive the drug by infusion in different schedules, and researchers will …
Phase: NA • Sponsor: Beijing GoBroad Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New mRNA shot aims to calm stubborn autoimmune diseases
Disease control Not yet recruitingThis early-phase study tests a new drug called WGb-0301 for people with autoimmune diseases (like lupus or autoimmune hepatitis) that haven't responded to standard treatments. The drug uses mRNA technology to target and clear certain immune cells (B cells) that are causing the di…
Phase: EARLY_PHASE1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Could one antibiotic dose before tooth pulling prevent infections in Immune-Weakened patients?
Prevention Not yet recruitingThis study tests whether a single dose of amoxicillin before a simple tooth extraction can prevent infections in people with autoimmune rheumatic diseases who are on immune-suppressing medications. Researchers will compare infection rates between those who get the antibiotic and …
Phase: PHASE4 • Sponsor: University of Sao Paulo General Hospital • Aim: Prevention
Last updated Aug 08, 2026 00:03 UTC
-
Yearly TB check may shield vulnerable patients from a hidden threat
Prevention Not yet recruitingThis trial investigates whether annual re-screening for tuberculosis infection using a blood test (IGRA) can prevent active TB in people with autoimmune rheumatic diseases who are taking biologic or immunosuppressive medications. Participants who initially test negative for TB ar…
Phase: NA • Sponsor: University of Sao Paulo General Hospital • Aim: Prevention
Last updated Aug 02, 2026 00:00 UTC
-
Blood fats and nanoparticles may reveal hidden clues in autoimmune liver disease
Knowledge-focused Not yet recruitingThis study looks at two types of liver disease — autoimmune hepatitis and non-alcoholic fatty liver disease — to see if fats in blood cells and tiny particles called extracellular vesicles differ between them. Researchers will collect blood samples from 24 adults and analyze thes…
Sponsor: Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis • Aim: Knowledge-focused
Last updated Jul 17, 2026 00:00 UTC
-
800-Patient study aims to unlock secrets of autoimmune liver disease
Knowledge-focused Not yet recruitingThis French study will collect medical data and biological samples from 800 people with autoimmune liver diseases. Researchers hope to identify new markers that explain why some patients respond well to treatment while others do not. The goal is to better understand the immune me…
Sponsor: Nantes University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:03 UTC
-
Can hospitals boost vaccine access for the most vulnerable?
Knowledge-focused Not yet recruitingThis study will test a new way to offer vaccines to vulnerable patients—those with chronic diseases or weakened immune systems—during hospital visits. Researchers will see if offering, prescribing, and giving vaccines in the hospital increases how many people get vaccinated. The …
Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC